A detailed history of Navellier & Associates Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Navellier & Associates Inc holds 24,971 shares of LLY stock, worth $19.4 Million. This represents 3.14% of its overall portfolio holdings.

Number of Shares
24,971
Previous 26,699 6.47%
Holding current value
$19.4 Million
Previous $24.2 Million 8.48%
% of portfolio
3.14%
Previous 2.88%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$772.14 - $960.02 $1.33 Million - $1.66 Million
-1,728 Reduced 6.47%
24,971 $22.1 Million
Q2 2024

Aug 08, 2024

BUY
$724.87 - $909.04 $793,007 - $994,489
1,094 Added 4.27%
26,699 $24.2 Million
Q1 2024

May 13, 2024

BUY
$592.2 - $792.28 $887,707 - $1.19 Million
1,499 Added 6.22%
25,605 $19.9 Million
Q4 2023

Feb 08, 2024

BUY
$525.19 - $619.13 $1.18 Million - $1.4 Million
2,254 Added 10.31%
24,106 $14.1 Million
Q3 2023

Nov 09, 2023

BUY
$434.7 - $599.3 $3.97 Million - $5.47 Million
9,125 Added 71.7%
21,852 $11.7 Million
Q2 2023

Aug 07, 2023

SELL
$350.74 - $468.98 $106,624 - $142,569
-304 Reduced 2.33%
12,727 $5.97 Million
Q1 2023

May 12, 2023

SELL
$310.63 - $364.82 $1.15 Million - $1.36 Million
-3,718 Reduced 22.2%
13,031 $4.48 Million
Q4 2022

Feb 02, 2023

SELL
$321.55 - $374.67 $275,889 - $321,466
-858 Reduced 4.87%
16,749 $6.13 Million
Q3 2022

Nov 09, 2022

SELL
$296.48 - $337.87 $108,808 - $123,998
-367 Reduced 2.04%
17,607 $5.69 Million
Q2 2022

Aug 12, 2022

BUY
$278.73 - $327.27 $5.01 Million - $5.88 Million
17,974 New
17,974 $5.83 Million
Q2 2021

Aug 09, 2021

SELL
$180.55 - $233.54 $361,100 - $467,080
-2,000 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$164.32 - $212.72 $16,432 - $21,272
-100 Reduced 4.76%
2,000 $374,000
Q2 2020

Aug 12, 2020

SELL
$136.42 - $164.18 $13,641 - $16,418
-100 Reduced 4.55%
2,100 $345,000
Q1 2020

May 13, 2020

BUY
$119.05 - $147.35 $23,810 - $29,470
200 Added 10.0%
2,200 $305,000
Q4 2019

Feb 12, 2020

BUY
$106.92 - $132.43 $21,384 - $26,486
200 Added 11.11%
2,000 $263,000
Q3 2019

Oct 16, 2019

SELL
$106.79 - $116.16 $10,679 - $11,616
-100 Reduced 5.26%
1,800 $201,000
Q2 2019

Jul 17, 2019

BUY
$110.79 - $129.32 $11,079 - $12,932
100 Added 5.56%
1,900 $211,000
Q1 2019

May 15, 2019

SELL
$111.31 - $131.02 $11,131 - $13,102
-100 Reduced 5.26%
1,800 $234,000
Q4 2018

Jan 15, 2019

SELL
$105.9 - $118.64 $24,357 - $27,287
-230 Reduced 10.8%
1,900 $220,000
Q3 2018

Nov 14, 2018

SELL
$85.86 - $107.31 $23,182 - $28,973
-270 Reduced 11.25%
2,130 $229,000
Q2 2018

Aug 06, 2018

BUY
$75.7 - $86.88 $181,680 - $208,512
2,400 New
2,400 $205,000
Q1 2018

May 21, 2018

SELL
$74.21 - $87.6 $260,625 - $307,651
-3,512 Closed
0 $0
Q4 2017

Feb 12, 2018

SELL
$81.94 - $87.89 $548,998 - $588,863
-6,700 Reduced 65.61%
3,512 $297,000
Q3 2017

Nov 14, 2017

SELL
$77.07 - $85.54 $415,253 - $460,889
-5,388 Reduced 34.54%
10,212 $874,000
Q2 2017

Aug 24, 2017

BUY
N/A
15,600
15,600 $1.28 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Navellier & Associates Inc Portfolio

Follow Navellier & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Navellier & Associates Inc with notifications on news.